Last reviewed 2026-05-18 · How we verify

anti-CGRP-mAbs

Clínica de Intervención en Neurociencias · Phase 1 active Small molecule Quality 55/100

anti-CGRP-mAbs is a Anti-CGRP monoclonal antibody Small molecule drug developed by Clínica de Intervención en Neurociencias. It is currently in Phase 1 development.

Monoclonal antibodies that bind to CGRP or its receptor, blocking the neuropeptide's role in migraine pain transmission and neurogenic inflammation.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	anti-CGRP-mAbs
Sponsor	Clínica de Intervención en Neurociencias
Drug class	Anti-CGRP monoclonal antibody
Modality	Small molecule
Phase	Phase 1

Mechanism of action

CGRP is a neuropeptide released during migraine attacks that causes vasodilation and pain transmission. Anti-CGRP monoclonal antibodies either bind directly to CGRP ligand or to its receptor, preventing CGRP from activating pain pathways and reducing migraine frequency and severity.

Approved indications

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

anti-CGRP-mAbs CI brief — competitive landscape report
anti-CGRP-mAbs updates RSS · CI watch RSS
Clínica de Intervención en Neurociencias portfolio CI

Frequently asked questions about anti-CGRP-mAbs

What is anti-CGRP-mAbs?

anti-CGRP-mAbs is a Anti-CGRP monoclonal antibody drug developed by Clínica de Intervención en Neurociencias.

How does anti-CGRP-mAbs work?

Monoclonal antibodies that bind to CGRP or its receptor, blocking the neuropeptide's role in migraine pain transmission and neurogenic inflammation.

Who makes anti-CGRP-mAbs?

anti-CGRP-mAbs is developed by Clínica de Intervención en Neurociencias (see full Clínica de Intervención en Neurociencias pipeline at /company/cl-nica-de-intervenci-n-en-neurociencias).

What drug class is anti-CGRP-mAbs in?

anti-CGRP-mAbs belongs to the Anti-CGRP monoclonal antibody class. See all Anti-CGRP monoclonal antibody drugs at /class/anti-cgrp-monoclonal-antibody.

What development phase is anti-CGRP-mAbs in?

anti-CGRP-mAbs is in Phase 1.

Drug class: All Anti-CGRP monoclonal antibody drugs
Manufacturer: Clínica de Intervención en Neurociencias — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing